跳轉至內容
Merck
  • Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis.

Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis.

Respirology (Carlton, Vic.) (2017-06-02)
Francesco Bonella, Xiaoping Long, Xuan He, Shinichiro Ohshimo, Matthias Griese, Josune Guzman, Ulrich Costabel
摘要

Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by alveolar filling. YKL-40, a chitinase-like protein produced by macrophages and epithelial cells, is increased in patients with interstitial lung diseases. We aimed to evaluate the role of YKL-40 as a biomarker for PAP. A total of 34 patients with autoimmune PAP and 50 healthy controls were studied. YKL-40 was measured by ELISA in serum and bronchoalveolar lavage fluid (BALF). Chitinase coding gene polymorphisms (CHI3L1-329 and -131) were detected by PCR and pyrosequencing. Correlations between serum YKL-40 levels and disease outcome were analysed. Baseline serum and BALF levels of YKL-40 were higher in PAP patients than in controls (286 ± 27 ng/mL vs 42 ± 4 ng/mL, P < 0.0001; 323 ± 36 ng/mL vs 3 ± 1 ng/mL, P < 0.0001, respectively). Serum YKL-40 levels correlated with diffusing capacity of the lung for carbon monoxide (DL YKL-40 is elevated in serum and BALF of PAP patients, and may be of clinical utility to predict outcome in PAP.